The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Displacement of Serotonin and Dopamine Transporters by Venlafaxine Extended Release Capsule at Steady State: A [123I]2β-Carbomethoxy-3β-(4-Iodophenyl)-Tropane Single Photon Emission Computed Tomography Imaging Study
Abstract
Both positron emission tomography and single photon emission computed tomography (SPECT) studies suggest that saturation of serotonin transporters (SERT) is present during treatment with therapeutic doses of selective serotonin reuptake inhibitors (SSRIs). Selective serotonin reuptake inhibitors also appear to increase the availability of dopamine transporters (DAT). The current study measured SERT occupancy and modulation of DAT by the serotonin/norepinephrine reuptake inhibitor (SNRI) venlafaxine using [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane SPECT. Eight healthy subjects were administered open-label venlafaxine extended release capsules (75 mg/d for 4 days followed by 150 mg/d for 5 days). Venlafaxine significantly inhibited [123I]beta-CIT binding to SERT in the brainstem (55.4%) and the diencephalon (54.1%). In contrast, venlafaxine increased [123I]beta-CIT binding to DAT in the striatum (10.1%) after 5 days of administration of 150 mg/d. The displacement of [123I]beta-CIT from brain SERT and the increase in striatal [123I]beta-CIT binding to DAT appear similar to previous work with the SSRI citalopram (40 mg/d). A literature review of SERT occupancy by marketed SSRIs and the SNRI venlafaxine using SPECT ([123I]beta-CIT) or positron emission tomography ([11C](N, N-Dimethyl-2-(2-amino-4-cyanophenylthio)-benzylamine) imaging suggests that therapeutic doses of SNRI are associated with virtual saturation of the serotonin transporter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As SSRIs, SNRIs, and serotonin modulators are not selective to SERT [49–52]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [51]
In the citing paper
“Venlafaxine main active metabolite, desvenlafaxine, presents with large levels of NE transporter inhibitory activities, further increasing levels of DA turnover in the prefrontal cortex (Shang et al., 2007).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Shang et al., 2007
In the citing paper
“Hence, if DA is released, it is free to circulate from the synapses, with huge prefrontal cortex levels of DA increase being recorded (Shang et al., 2007).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Shang et al., 2007
In the citing paper
“Preclinical studies showed that venlafaxine presents with a high affinity for D2 receptors (Bolden-Watson and Richelson, 1993; Shang et al., 2007), whilst its chronic administration is associated as well with D3 receptors' adaptive changes.”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Shang et al., 2007
In the citing paper
“Both venlafaxine and its metabolite do not possess any monoamine oxidase inhibitory activity, which is responsible for the degradation of DA (Maj and Rogóz, 1999; Shang et al., 2007).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Shang et al., 2007
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 3×
“Positron emission tomography studies using [(11)C]DASB found approximately 80% occupancy of the SERT in striatum by both citalopram (up to 60 mg/d) and venlafaxine (up to 225 mg/d) in patients with depression.(11,12) Such a discrepancy may be potentially attributed to different tracer kinetics and characteristics betw…”
BackgroundMethodMonoamine dysfunction and the pathophysiology and treatment of depression.
Charney, D. S. (1998) · PubMed · Cited by 395
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Laruelle, M., Wallace, E., Seibyl, J. P., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S. S., Neumeyer, J. L., Charney, D. S., Hoffer, P. B., & Innis, R. B. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.131 · Cited by 268
Self-citationEntsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Ginovart, N., Wilson, A. A., Meyer, J. H., Hussey, D., & Houle, S. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200111000-00010 · Cited by 209
Kugaya, A., Seneca, N. M., Snyder, P. J., Williams, S. A., Malison, R. T., Baldwin, R. M., Seibyl, J. P., & Innis, R. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300036 · Cited by 162
Self-citation?-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo
Pirker, W., Asenbaum, S., Kasper, S. F., Walter, H., Angelberger, P., Koch, G., Pozzera, A., Deecke, L., Podreka, I., & Br�cke, T. (1995) · Journal of Neural Transmission · doi:10.1007/bf01276462 · Cited by 127
Research works printed but not linked: 7
- Thase, 2003, J Clin Psychiatry, 64, 18, 10.4088/JCP.v64n1116b · DOI
- Thase, 2003, J Clin Psychiatry, 64, 3, 10.4088/JCP.v64n1116b · DOI
- Demitrack, 2002, J Clin Psychiatry, 63, 14
- Skolnick, 2002, J Clin Psychiatry, 63, 19
- Charney, 1998, J Clin Psychiatry, 59, 11
- Owens, 1997, J Pharmacol Exp Ther, 283, 1305
- Seibyl, 1994, J Nucl Med, 35, 764
Cited by
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
Sramek, J. J., Hardy, L. W., Bieck, P., Zamora, C., Versavel, M., Kharidia, J., Grinnell, T., Chen, Y., Sullivan, M., Ding, H., et al. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12513 · Cited by 5
“Nausea and vomiting may reflect the compound’s activity on serotonin reuptake, as similar effects have been reported both with SSRIs [44,45] and with SNRIs [46,47].”
Background
Metadata
- Authors
- Shang, Y., Gibbs, M. A., Marek, G. J., Stiger, T., Burstein, A. H., Marek, K., Seibyl, J. P., & Rogers, J. F.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Shang, Yili
- Gibbs, Megan A.
- Marek, Gerard J.
- Stiger, Thomas
- Burstein, Aaron H.
- Rogers, Janyce F.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-02
- Volume
- 27
- Issue
- 1
- Pages
- 71-75
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1983944942
- Cited by
- 36
- References
- 24
- Citations by year
- 2026: 3 · 2024: 2 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 5
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- venlafaxine, serotonin transporter, dopamine transporter, [123I]beta-CIT, [11C]DASB, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, striatum, brainstem, diencephalon, citalopram
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Capsules, Cocaine, Cyclohexanols, Delayed-Action Preparations, Humans, Iodine Radioisotopes, Tomography, Emission-Computed, Single-Photon, Selective Serotonin Reuptake Inhibitors, Radiopharmaceuticals, Dopamine Plasma Membrane Transport Proteins, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Displacement of Serotonin and Dopamine Transporters by Venlafaxine Extended Release Capsule at Steady State: A [123I]2β-Carbomethoxy-3β-(4-Iodophenyl)-Tropane Single Photon Emission Computed Tomography Imaging Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e31802e0017
- The paper
- Shang, Y., Gibbs, M. A., Marek, G. J., Stiger, T., Burstein, A. H., Marek, K., Seibyl, J. P., & Rogers, J. F. (2007). Displacement of Serotonin and Dopamine Transporters by Venlafaxine Extended Release Capsule at Steady State: A [123I]2β-Carbomethoxy-3β-(4-Iodophenyl)-Tropane Single Photon Emission Computed Tomography Imaging Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31802e0017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.